The in vitro antitumour activity studies on a panel of human cancer cell lines (A549, HeLa, G-361, A2780, and A2780R) and the combined in vivo and ex vivo antitumour testing on the L1210 lymphocytic leukaemia model were performed on the cis-[PtCl2(naza)2] complexes (1-3) involving the 7-azaindole derivatives (naza). The platinum(II) complexes showed significantly higher in vitro cytotoxic effects on cell-based models, as compared with cisplatin, and showed the ability to avoid the acquired resistance of the A2780R cell line to cisplatin. The in vivo testing of the complexes (applied at the same dose as cisplatin) revealed their positive effect on the reduction of cancerous tissues volume, even if it is lower than that of cisplatin, however, they also showed less serious adverse effects on the healthy tissues and the health status of the treated mice. The results of ex vivo assays revealed that the complexes 1-3 were able to modulate the levels of active forms of caspases 3 and 8, and the transcription factor p53, and thus activate the intrinsic (mitochondrial) pathway of apoptosis. The pharmacological observations were supported by both the histological and immunohistochemical evaluation of isolated cancerous tissues. The applicability of the prepared complexes and their fate in biological systems, characterized by the hydrolytic stability and the thermodynamic aspects of the interactions with cysteine, reduced glutathione, and human serum albumin were studied by the mass spectrometry and isothermal titration calorimetric experiments.

Department of Cell Biology and Genetics Regional Centre of Advanced Technologies and Materials Faculty of Science Palacký University Olomouc Czech Republic

Department of Human Pharmacology and Toxicology Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Department of Inorganic Chemistry Regional Centre of Advanced Technologies and Materials Faculty of Science Palacký University Olomouc Czech Republic

Zobrazit více v PubMed

Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nature Rev Cancer 7: 573–584. PubMed

Kelland LR, Farrell NP (2000) Platinum-Based Drugs in Cancer Therapy. Humana: Totowa.

Rosenberg B, VanCamp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699. PubMed

Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinum compounds - a new class of potent antitumour agents. Nature 222: 385–386. PubMed

Harrap KR (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat Rev 12: 21–33. PubMed

Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, et al. (1992) Phase II study of cis-diammine(glycolato)platinum, 254–S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Pharmacol 31: 187–192. PubMed

Kidani Y, Inagaki K, Iigo M, Hoshi A, Kuretani K (1978) Anti-tumor activity of 1,2-diaminocyclohexaneplatinum complexes against sarcoma-180 ascites form. J Med Chem 21: 1315–1318. PubMed

McKeage MJ (2001) Lobaplatin: a new antitumour platinum drug. Expert Opin Inv Drugs 10: 119–128. PubMed

Shen DW, Pouliot LM, Hall MD, Gottesman MM (2012) Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes. Pharmacol Rev 64: 706–721. PubMed PMC

Galanski M, Yasemi A, Slaby S, Jakupec MA, Arion VB, et al. (2004) Synthesis, crystal structure and cytotoxicity of new oxaliplatin analogues indicating that improvement of anticancer activity is still possible. Eur J Med Chem 39: 707–714. PubMed

Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77: 366–373. PubMed PMC

Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, et al. (1998) Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum coordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473). Anticancer Drug Design 13: 1–18. PubMed

Sharp SY, O'Neill CF, Rogers PM, Boxall FE, Kelland LR (2002) Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. Eur J Cancer 38: 2309–2315. PubMed

Wheate NJ, Walker S, Craig GE, Oun R (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39: 8113–8127. PubMed

Pogozheva D, Baudrona SA, Rogez G, Hosseini MW (2013) From discrete tricyanovinylene appended 7-azaindole copper(II) paddlewheel to an infinite 1D network: Synthesis, crystal structure and magnetic properties. Polyhedron 52: 1329–1335.

Tsoureas N, Nunn J, Bevis T, Haddow MF, Hamilton A, et al. (2011) Strong agostic-type interactions in ruthenium benzylidene complexes containing 7-azaindole based scorpionate ligands. Dalton Trans 40: 951–958. PubMed

Ruiz J, Rodríguez V, de Haro C, Espinosa A, Péerez J, et al. (2010) New 7-azaindole palladium and platinum complexes: crystal structures and theoretical calculations. In vitro anticancer activity of the platinum compounds. Dalton Trans 39: 3290–3301. PubMed

Pierce LT, Cahill MM, Winfield HJ, McCarthy FO (2012) Synthesis and identification of novel indolo[2,3-a]pyrimido[5,4-c]carbazoles as a new class of anti-cancer agents. Eur J Med Chem 56: 292–300. PubMed

Hong S, Kim J, Seo JH, Jung KH, Hong SS, et al. (2012) Design, Synthesis, and Evaluation of 3,5-Disubstituted 7-Azaindoles as Trk Inhibitors with Anticancer and Antiangiogenic Activities. J Med Chem 55: 5337–5349. PubMed

Chevé G, Bories C, Fauvel B, Picot F, Tible A, et al. (2012) De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases. Med Chem Commun 3: 788–800.

Dyke HJ, Price S, Williams K (2010) US Patent 20100216768.

Štarha P, Marek J, Trávníček Z (2012) Cisplatin and oxaliplatin derivatives involving 7-azaindole: Structural characterisations. Polyhedron 33: 404–409.

Štarha P, Trávníček Z, Popa A, Popa I, Muchová T, et al. (2012) How to modify 7-azaindole to form cytotoxic Pt(II) complexes: Highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole. J Inorg Biochem 115: 57–63. PubMed

Muchová T, Prachařová J, Štarha P, Olivová R, Vrána O, et al. (2013) Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells. J Biol Inorg Chem 18: 579–589. PubMed

Salemi G, Gueli MC, D'Amelio M, Saia V, Mangiapane P, et al. (2009) Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurol Sci 30: 361–364. PubMed

Trávníček Z, Matiková-Maľarová M, Novotná R, Vančo J, Štěpánková K, et al. (2011) In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivates with higher pro-apoptotic activity than NAMI-A. J Inorg Biochem 105: 937–948. PubMed

Talhouk R, Chin J, Unemori E, Werb Z, Bissell M (1991) Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development 112: 439–49. PubMed PMC

Reedijk J (1999) Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99: 2499–2510. PubMed

Nagle PS, Rodriguez F, Nguyen B, Wilson WD, Rozas I (2012) High DNA Affinity of a Series of Peptide Linked Diaromatic Guanidinium-like Derivatives. J Med Chem 55: 4397–4406. PubMed

Spuches AM, Kruszyna HG, Rich AM, Wilcox DE (2006) Thermodynamics of the As(III)-Thiol Interaction: Arsenite and Monomethylarsenite Complexes with Glutathione, Dihydrolipoic Acid, and Other Thiol Ligands. Inorg Chem 44: 2964–2972. PubMed

Timerbaev AR, Hartinger CG, Aleksenko SS, Keppler BK (2006) Interactions of Antitumour Metallodrugs with Serum Proteins: Advances in Characterization Using Modern Analytical Methodology. Chem Rev 106: 2224–2248. PubMed

Esposito BA, Najjar R (2002) Interactions of antitumoural platinum-group metallodrugs with albumin. Coord Chem Rev 232: 137–149.

Brown SD, Trotter KD, Sutcliffe OB, Plumb JA, Waddell B, et al. (2012) Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity. Dalton Trans 41: 11330–11339. PubMed

Carreira M, Calvo-Sanjuán R, Sanaú M, Zhao X, Magliozzo RS, et al. (2012) Cytotoxic hydrophilic iminophosphorane coordination compounds of d8 metals. Studies of their interactions with DNA and HSA. J Inorg Biochem 116: 204–214. PubMed PMC

Quirante J, Ruiz D, Gonzalez A, López C, Cascante M, et al. (2011) Platinum(II) and palladium(II) complexes with (N,N′) and (C,N,N′)− ligands derived from pyrazole as anticancer and antimalarial agents: Synthesis, characterization and in vitro activities. J Inorg Biochem 105: 1720–1728. PubMed

Carland M, Grannas MJ, Cairns MJ, Roknic VJ, Denny WA, et al. (2010) Substituted 9-aminoacridine-4-carboxamides tethered to platinum(II)diamine complexes: Chemistry, cytotoxicity and DNA sequence selectivity. J Inorg Biochem 104: 815–819. PubMed

Vrzal R, Štarha P, Dvořák Z, Trávníček Z (2010) Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands. J Inorg Biochem 104: 1130–1132. PubMed

de Mier-Vinué J, Gay M, Montaña AM, Sáez RI, Moreno V, et al. (2008) Synthesis, biophysical studies, and antiproliferative activity of platinum(II) complexes having 1,2-bis(aminomethyl)carbobicyclic ligands. J Med Chem 51: 424–431. PubMed

Yamori T (2003) Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52: S74–S79. PubMed

Margiotta N, Denora N, Ostuni R, Laquintana V, Anderson A, et al. (2010) Platinum(II) complexes with bioactive carrier ligands having high affinity for the translocator protein. J Med Chem 53: 5144–5154. PubMed

Xu G, Yan Z, Wamg N, Liu Z (2011) Synthesis and cytotoxicity of cis-dichloroplatinum (II) complexes of (1S,3S)-1,2,3,4-tetrahydroisoquinolines. Eur J Med Chem 46: 356–363. PubMed

Komeda S, Takayama H, Suzuki T, Odani A, Yamori T, et al. (2013) Synthesis of antitumour azolato-bridged dinuclear platinum(II) complexes within vivo antitumour efficacy and uniquein vitro cytotoxicity profiles. Metallomics 5: 461–468. PubMed

World Health Organization (2009) World Health Statistics 2009. Available: http://www.who.int/whosis/whostat/2009/en/. Accessed 2014 Feb 13.

Hua H, Li M, Luo T, Yin Y, Jiang Y (2011) Matrix metalloproteinases in tumourigenesis: an evolving paradigm. Cell Mol Life Sci 68: 3853–3868. PubMed PMC

Zhang B, Ramesh G, Uematsu S, Akira S, Reevers WB (2008) TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity. J Am Soc Nephrol 19: 923–932. PubMed PMC

Reedijk J (1987) The mechanism of action of platinum anti-tumor drugs. Pure Appl Chem 59: 181–192.

Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265–7279. PubMed

Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR (1998) The p53 Network. J Biol Chem 273: 1–4. PubMed

Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, et al. (1999) The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399: 806–809. PubMed

Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770–776. PubMed

Chauhan P, Sodhi A, Shrivastava A (2009) Cisplatin primes murine peritoneal macrophages for enhanced expression of nitric oxide, proinflammatory cytokines, TLRs, transcription factors and activation of MAP kinases upon co-incubation with L929cells. Immunobiology 214: 197–209. PubMed

Platinum(II)-oxalato complexes of seliciclib (CYC202) derivatives show different cellular effects and lesser adverse effects in mouse lymphoma model than cisplatin

In vitro anticancer active cis-Pt(II)-diiodido complexes containing 4-azaindoles

Platinum(II) Iodido Complexes of 7-Azaindoles with Significant Antiproliferative Effects: An Old Story Revisited with Unexpected Outcomes

Organometallic Half-Sandwich Dichloridoruthenium(II) Complexes with 7-Azaindoles: Synthesis, Characterization and Elucidation of Their Anticancer Inactivity against A2780 Cell Line

Highly and Broad-Spectrum In Vitro Antitumor Active cis-Dichloridoplatinum(II) Complexes with 7-Azaindoles

Potentiating effect of UVA irradiation on anticancer activity of Carboplatin derivatives involving 7-azaindoles

Gold(I)-triphenylphosphine complexes with hypoxanthine-derived ligands: in vitro evaluations of anticancer and anti-inflammatory activities